TW201000126A - Glucagon receptor antagonists - Google Patents

Glucagon receptor antagonists Download PDF

Info

Publication number
TW201000126A
TW201000126A TW098108296A TW98108296A TW201000126A TW 201000126 A TW201000126 A TW 201000126A TW 098108296 A TW098108296 A TW 098108296A TW 98108296 A TW98108296 A TW 98108296A TW 201000126 A TW201000126 A TW 201000126A
Authority
TW
Taiwan
Prior art keywords
ser
leu
val
thr
gly
Prior art date
Application number
TW098108296A
Other languages
English (en)
Chinese (zh)
Inventor
Rohn Lee Millican Jr
Andrew Ihor Korytko
Brian John Ondek
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40794248&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW201000126(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of TW201000126A publication Critical patent/TW201000126A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW098108296A 2008-03-27 2009-03-13 Glucagon receptor antagonists TW201000126A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3990708P 2008-03-27 2008-03-27

Publications (1)

Publication Number Publication Date
TW201000126A true TW201000126A (en) 2010-01-01

Family

ID=40794248

Family Applications (1)

Application Number Title Priority Date Filing Date
TW098108296A TW201000126A (en) 2008-03-27 2009-03-13 Glucagon receptor antagonists

Country Status (15)

Country Link
US (2) US7968686B2 (enExample)
EP (1) EP2268670A1 (enExample)
JP (1) JP5438095B2 (enExample)
KR (1) KR101235934B1 (enExample)
CN (1) CN101983208A (enExample)
AR (1) AR070844A1 (enExample)
AU (1) AU2009228866A1 (enExample)
BR (1) BRPI0910118A2 (enExample)
CA (1) CA2719761A1 (enExample)
CL (1) CL2009000586A1 (enExample)
EA (1) EA201071126A1 (enExample)
MX (1) MX2010010517A (enExample)
PE (1) PE20091674A1 (enExample)
TW (1) TW201000126A (enExample)
WO (1) WO2009120530A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012005208A2 (pt) * 2009-09-08 2016-11-22 Neopharm Co Ltd antiocorpos contra o receptor de glucagon e seu uso
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
US8771696B2 (en) 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
DK2663579T3 (en) 2011-01-14 2017-07-31 Univ California THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013059531A1 (en) * 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
JP2015505828A (ja) 2011-12-02 2015-02-26 イーライ リリー アンド カンパニー 抗グルカゴン抗体およびその使用
WO2014181229A2 (en) * 2013-05-07 2014-11-13 Rinat Neuroscience Corp. Anti-glucagon receptor antibodies and methods of use thereof
US10626179B2 (en) 2014-06-08 2020-04-21 Remd Biotherapeutics, Inc. Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies
CN118236497A (zh) 2016-08-30 2024-06-25 瑞泽恩制药公司 通过干扰胰高血糖素受体的信号传导治疗重度胰岛素抵抗的方法
EP3529278A1 (en) 2016-10-20 2019-08-28 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
SG11201906682YA (en) 2017-01-27 2019-08-27 Ngm Biopharmaceuticals Inc Glucagon receptor binding proteins and methods of use thereof
CA3071387A1 (en) 2017-08-22 2019-02-28 Regeneron Pharmaceuticals, Inc. Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
CN110357959B (zh) * 2018-04-10 2023-02-28 鸿运华宁(杭州)生物医药有限公司 Gcgr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用
EP3829636A1 (en) 2018-07-27 2021-06-09 NGM Biopharmaceuticals, Inc. Use of glucagon receptor antagonists with immunotherapeutic agent
CN115947849A (zh) 2018-12-21 2023-04-11 江苏恒瑞医药股份有限公司 双特异性蛋白

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3515112B2 (ja) 1992-08-28 2004-04-05 ノボ ノルディスク アクティーゼルスカブ グルカゴン・レセプタ
US5776725A (en) 1992-08-28 1998-07-07 Zymogenetics, Inc. Recombinant production of glucagon receptors
AU2002239538A1 (en) 2000-12-06 2002-06-18 Deltagen, Inc. Transgenic mice containing glucagon receptor gene disruptions
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
US7399853B2 (en) 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
WO2006005469A2 (en) 2004-07-15 2006-01-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr)
JP5001364B2 (ja) 2006-07-04 2012-08-15 ブラッコ イメージング ソチエタ ペル アチオニ 腫瘍性組織等の生物組織を局部的に熱剥離するための装置
CL2007002668A1 (es) * 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.

Also Published As

Publication number Publication date
CN101983208A (zh) 2011-03-02
US20090252727A1 (en) 2009-10-08
MX2010010517A (es) 2010-12-20
BRPI0910118A2 (pt) 2015-12-29
US7968686B2 (en) 2011-06-28
AR070844A1 (es) 2010-05-05
KR20100117130A (ko) 2010-11-02
KR101235934B1 (ko) 2013-02-21
US20110212092A1 (en) 2011-09-01
JP2011518125A (ja) 2011-06-23
EA201071126A1 (ru) 2011-04-29
AU2009228866A1 (en) 2009-10-01
CL2009000586A1 (es) 2010-06-04
JP5438095B2 (ja) 2014-03-12
WO2009120530A1 (en) 2009-10-01
PE20091674A1 (es) 2009-11-04
CA2719761A1 (en) 2009-10-01
EP2268670A1 (en) 2011-01-05

Similar Documents

Publication Publication Date Title
TW201000126A (en) Glucagon receptor antagonists
TWI718206B (zh) Pd-l1抗體、其抗原結合片段及其醫藥用途
US9447182B2 (en) Antibodies directed against the alpha chain of IL7 receptor—their use for the preparation of drug candidates
EP2513147B1 (en) Novel antagonist antibodies and their fab fragments against gpvi and uses thereof
CN109069622A (zh) 特异性结合人cd40的拮抗性抗体和使用方法
EP3445784B1 (en) Administration of a bispecific construct binding to cd33 and cd3 for use in a method for the treatment of myeloid leukemia
CN110678484B (zh) 抗pd-l1/抗lag3双特异性抗体及其用途
AU2018278051A1 (en) Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof
KR20210041585A (ko) 항 btla 항체
TW201922798A (zh) 靶向rankl的治療性抗體
EP3524624A1 (en) Anti-cd27 antibody, antigen-binding fragment thereof, and medical use of same
US20220153853A1 (en) Bispecific protein
EP2336188A1 (en) Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof
CA3239307A1 (en) Caninized antibodies to canine interleukin-31 receptor alpha 1
EP2397495A1 (en) Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof
EP2402371A1 (en) Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof
HK1170251B (en) Novel antagonist antibodies and their fab fragments against gpvi and uses thereof